Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Total Current Liabilities (2019 - 2025)

Harmony Biosciences Holdings' Total Current Liabilities history spans 7 years, with the latest figure at $252.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 44.01% year-over-year to $252.1 million; the TTM value through Dec 2025 reached $252.1 million, up 44.01%, while the annual FY2025 figure was $252.1 million, 44.01% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $252.1 million at Harmony Biosciences Holdings, up from $223.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $252.1 million in Q4 2025 and bottomed at $33.4 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $100.2 million (2022), against an average of $116.4 million.
  • The largest annual shift saw Total Current Liabilities tumbled 60.03% in 2021 before it soared 125.43% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $53.8 million in 2021, then soared by 46.69% to $78.9 million in 2022, then surged by 107.62% to $163.8 million in 2023, then rose by 6.9% to $175.1 million in 2024, then surged by 44.01% to $252.1 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Total Current Liabilities are $252.1 million (Q4 2025), $223.4 million (Q3 2025), and $180.1 million (Q2 2025).